<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02392442</url>
  </required_header>
  <id_info>
    <org_study_id>150091</org_study_id>
    <secondary_id>15-CC-0091</secondary_id>
    <nct_id>NCT02392442</nct_id>
  </id_info>
  <brief_title>Effects of Bronchial Segmental Endotoxin Instillation in Humans</brief_title>
  <official_title>Pulmonary Effects of Bronchial Segmental Endotoxin Instillation in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:

      - When bacteria enter the lungs, serious infections can occur. Researchers want to learn more
      about the process of inflammation in the lungs by studying lung cells and the products that
      they make. Lung cells are influenced by infections, smoking, and molecules made within the
      body. Researchers also want to learn more about one of these molecules, called microRNA (or
      micro ribonucleic acid).

      Objective:

      - To better how the body responds to infection. Also, to understand which cells in the lung
      secrete microRNA and how they may influence other lung cells.

      Eligibility:

      - Healthy, non-smoking adults ages 18-45.

      Design:

        -  Participants will be screened with a medical history and physical exam. They will have
           blood and urine tests and an electrocardiogram.

        -  Participants will have blood drawn from an arm vein. They will have an intravenous
           catheter (small plastic tube) placed in a vein.

        -  All participants will have bronchoscopy with bronchoalveolar lavage. They will be numbed
           with medicine. A thin flexible tube will be placed through the nasal passages or the
           mouth into the airways of the lung.

             -  Some participants will have bronchoscopy with bronchoalveolar lavage (rinsing the
                airways with salt water) in order to obtain cells from lung. The water will then be
                suctioned out.

             -  Some participants will have two bronchoscopies; during the first procedure,
                endotoxin, a molecule found in bacteria is squirted into a small portion of the
                lung. Endotoxin is a molecule that acts like an infection but isn t one. After 6 to
                48 hours, bronchoscopy with with bronchoalveolar lavage will be done to look at the
                lung s response to endotoxin.

        -  Participants heart rhythm and rate, temperature and blood oxygen level will be monitored
           during the procedures.

        -  Participants will be called the next day to see how they are feeling.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Defining the mechanisms that limit tissue injury during acute inflammation may provide the
      basis for preventing secondary organ dysfunction during serious infections. We plan to use
      the human endotoxin lung challenge model to study mechanisms associated with the initiation
      and resolution of lung inflammation.

      Endotoxin (LPS), an outer membrane component of Gram-negative bacteria, is a major microbial
      factor that mediates inflammation associated with serious infections. For over fifty years,
      endotoxin has been administered to humans as a challenge agent in order to understand basic
      mechanisms of inflammation, to provide a proof of principle for pharmacologic interventions
      (e.g., anti-cytokines, corticosteroids), or as an adjuvant for immunotherapy of malignancies.

      We previously developed a human model to study the initiation and resolution of inflammation
      in a lung segment following endotoxin bronchial instillation. The inflammatory response was
      limited to the challenged segment and had minimal associated systemic responses. After direct
      instillation into a lung segment, endotoxin elicits an inflammatory response characterized by
      the local production of inflammatory mediators, proteins and increases in cellularity. The
      predominate cell species found in the bronchoalveolar lavage (BAL) of the challenged segment
      changes from a neutrophil influx at 2 - 6 hours to an influx of monocytes and lymphocytes at
      24 and 48 hours following endotoxin challenge. At 6 hours, BAL pro-inflammatory activity
      (i.e., tumor necrosis factor bioactivity and induction of intercellular adhesion molecule-1
      on reporter cells) is present and absent at 24 and 48 hours post endotoxin. In addition,
      unique subsets of lymphocytes are present in the lung during this inflammatory response.

      We have recently shown that non-cellular microRNAs (miRNAs) are present in archived BAL from
      normal healthy volunteer airways and are differentially expressed 6 hours after
      endotoxin-induced acute lung inflammation. miRNA are single stranded non-coding RNA that
      mediate posttranscriptional regulation of gene expression. Some extracellular miRNA species
      may modulate local and distant cell processes. miRNA can activate Toll-like receptors (TLRs)
      and have been described as blood biomarkers of different disease states. However, the
      specific role of extracellular or secreted miRNAs in the lung is poorly defined. Our research
      plan is designed to study the roles of miRNA in acute lung inflammation by investigating the
      changes in miRNA signatures found in BAL and lung cells from healthy volunteers at baseline
      and at 6, 24, or 48 hours after endotoxin segmental lung challenge. A panel of flow cytometry
      cell surface markers will be performed on blood and BAL cells and intracellular and secreted
      miRNA will be isolated from specific cell species (i.e., neutrophils, monocytes, macrophages,
      and lymphocytes). We hypothesize that miRNA will have a role in modulating the initiation and
      resolution of inflammation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 18, 2015</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of cell-associated and secreted miRNA with specific types of resident and inflammatory cells in the lung.</measure>
    <time_frame>6, 24, or 48 hours after Endotoxin is instilled in the lung.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Acute Lung Inflammation</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A lung segment (either in the lingual of the left upperlobe or the right middle lobe) will be selected. Saline (10 mL) will be instilled into the one side using a balloon tipped catheter placed into a lung subsegment and then endotoxin (4 ng/kg in final volume of 2 ml) will be instilled using a balloon tipped catheter into theopposite lung subsegment and then flushed with 10mL of saline. A second BAL will be performed at either 6, 24, or 48 hours after Endotoxin instillation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Bronchoalveolar lavage performed with a total of 180of normal saline instilled in six 30 mL aliquots into the left (lingual) and right (middle lobe) lung segments (360 mL total).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>180 of normal saline instilled in six 30 mL aliquots into the left (lingual) and right (middle lobe) lung segments (360 mL total)</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Endotoxin</intervention_name>
    <description>4 ng/kg in final volume of 2 ml</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

               1. Healthy 18 to 45 year old, nonsmoking subjects based on screening examination and
                  laboratory tests.

               2. No significant active medical problems. This would include but not be limited to
                  any cardiac disorder (e.g. arrhythmia, valvular heart disease), pulmonary disease
                  (e.g. asthma requiring chronic medications, chronic bronchitis, emphysema),
                  neurologic disorder (e.g.

                  epilepsy), kidney disease (e.g. nephritis, nephrosis), rheumatologic disorder
                  (e.g. inflammatory arthritis), endocrine disorder (e.g. diabetes, thyroid
                  disease), liver disease (e.g. hepatitis), gastrointestinal disorder (e.g.
                  inflammatory bowel disease) or infectious

                  disease (e.g. human immunodeficiency virus).

               3. No concurrent medications including aspirin or non-steroidal anti-inflammatory
                  drugs or have not taken these for at least 7 days prior to study participation.

               4. Previous smokers would have to have abstained from cigarettes for at least one
                  year and have no greater than a 10-pack year smoking history. If you use a
                  hookah, e-cigarette, or vaping more than once a week, you must abstain for at
                  least 6 weeks prior to participating in the study.

               5. Females must be practicing active method of birth control or abstinence of sexual
                  activity.

               6. Must be willing to have samples stored

        EXCLUSION CRITERIA:

          1. Any serious active medical problem as defined above

          2. Pregnancy and/or lactation

          3. BMI &gt;30
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony F Suffredini, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institutes of Health Clinical Center (CC)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Debra Reda, R.N.</last_name>
    <phone>(301) 496-9320</phone>
    <email>dreda@nih.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anthony F Suffredini, M.D.</last_name>
    <phone>(301) 496-9320</phone>
    <email>asuffredini@mail.nih.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)</last_name>
      <phone>800-411-1222</phone>
      <phone_ext>TTY8664111010</phone_ext>
      <email>prpl@cc.nih.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2015-CC-0091.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>O'Grady NP, Preas HL, Pugin J, Fiuza C, Tropea M, Reda D, Banks SM, Suffredini AF. Local inflammatory responses following bronchial endotoxin instillation in humans. Am J Respir Crit Care Med. 2001 Jun;163(7):1591-8.</citation>
    <PMID>11401879</PMID>
  </reference>
  <reference>
    <citation>Janssen O, Schaumann F, Holz O, Lavae-Mokhtari B, Welker L, Winkler C, Biller H, Krug N, Hohlfeld JM. Low-dose endotoxin inhalation in healthy volunteers--a challenge model for early clinical drug development. BMC Pulm Med. 2013 Mar 28;13:19. doi: 10.1186/1471-2466-13-19.</citation>
    <PMID>23537365</PMID>
  </reference>
  <reference>
    <citation>Sandstr√∂m T, Bjermer L, Rylander R. Lipopolysaccharide (LPS) inhalation in healthy subjects increases neutrophils, lymphocytes and fibronectin levels in bronchoalveolar lavage fluid. Eur Respir J. 1992 Sep;5(8):992-6.</citation>
    <PMID>1426208</PMID>
  </reference>
  <verification_date>May 1, 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2015</study_first_submitted>
  <study_first_submitted_qc>March 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2015</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bronchoalveolar Lavage</keyword>
  <keyword>Bronchoscopy</keyword>
  <keyword>Endotoxin Instillation</keyword>
  <keyword>Immunophenotype</keyword>
  <keyword>miRNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

